ALLMedicine™ Adenosine Deaminase Deficiency Center

Dec 5th, 2022 - Balancing early detection of adenosine deaminase deficiency with overdiagnosis risk.|2022|Revak S,Shaker M,Sun D,|diagnosis,genetics,

Aug 2nd, 2022 - Newborn screening (NBS) by means of T cell receptor excision circles (TREC) is now universal in the United States, Puerto Rico, and the Navajo Nation as a strategy to identify severe combined immunodeficiency (SCID) in newborns. Owing to the chara...

May 12th, 2021 - Severe combined immunodeficiency due to adenosine deaminase (ADA) deficiency (ADA-SCID) is a rare and life-threatening primary immunodeficiency. We treated 50 patients with ADA-SCID (30 in the United States and 20 in the United Kingdom) with an in...

May 2nd, 2021 - We report the case of a 4-year-old boy, post-human stem cell transplantation for severe combined immunodeficiency (SCID) due to adenosine deaminase deficiency (ADA), who developed multiple dermatofibrosarcoma protuberans (DFSP). We hypothesize a r...

Dec 30th, 2020 - SCID are characterized by an imbalance in cellular and humoral immunity. Enzyme ADA deficiency represents from 10% to 15% of the SCID. This generates diminished maturation of the cell precursors. Treatments include enzyme replacement therapy, allo...

Dec 16th, 2016 - Low-dose methotrexate therapy suppresses autoimmune arthritis in human and animal models. We hypothesize that the effect of methotrexate in the treatment of rheumatoid arthritis is due to the inhibition of aminoimidazole-carboxamide ribotide trans...

Sep 14th, 2015 - Adenosine deaminase deficiency is an inherited disorder that results in severe abnormalities of the immune system and leaves children unable to fight infection. This trial aims to treat adenosine deaminase deficiency patients using gene therapy.

Dec 21st, 2022 - A gene therapy for a rare type of severe combined immunodeficiency (SCID) was safe and sufficiently restored T-cell immunity in an early trial, results from a phase I/II study showed. At a single center, all 10 infants with Artemis-deficient SCID ...

May 11th, 2021 - A novel gene therapy for severe combined immunodeficiency from adenosine deaminase deficiency (ADA-SCID) restored immune cell counts without death or need for enzyme replacement therapy, researchers reported. Survival without needing to re-initiat...

Apr 4th, 2016 - Editor’s note: The European Commission approved the gene therapy Strimvelis (GlaxoSmithKline) on May 27, 2016, to treat children with the very rare disease Severe Combined Immunodeficiency due to Adenosine Deaminase deficiency (ADA-SCID), accordin...

Jul 21st, 2010 - Action Points Explain to interested patients and parents that gene therapy for severe combined immunodeficiency disease (SCID) was shown to be safe for up to 10 years in a small number of patients with the lethal genetic disease. But caution that ...

Jan 28th, 2009 - Action Points Explain to interested patients that this study found that replacing a defective gene provided improvements in the immune systems of almost all of the children with severe combined immunodeficiency caused by lack of adenosine deaminas...